[{"id":"ccc06936-f76a-49da-b8fa-d22d094886ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05199519","created_at":"2022-01-20T14:53:32.658Z","updated_at":"2024-07-02T16:35:47.265Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345","source_id_and_acronym":"NCT05199519","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBI-345"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 10/29/2022","primary_completion_date":" 10/29/2022","study_txt":" Completion: 01/19/2023","study_completion_date":" 01/19/2023","last_update_posted":"2023-05-24"}]